Cephalon Inc.Provides Update on Regulatory Status of NUVIGIL(TM) Tablets.Cephalon Inc. announced that the United States Food and Drug Administration (FDA) has extended the action date for its review of the New Drug Application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] to improve wakefulness in patients suffering from excessive sleepiness associated with narcolepsy, shift work sleep disorder (SWSD) and obstructive sleep apnea/hypopnea syndrome (OSA/HS) to April 30, 2006.A NDA for NUVIGIL was filed with the FDA on March 31, 2005.The original action date under the Prescription Drug User Fee Act (PDUFA) for the NUVIGIL NDA was January 31, 2006.At the FDA's request, the company submitted additional information to FDA in October 2005.The FDA has informed the company that this submission has been classified as a major amendment to the NDA, which enables the FDA to extend the action date by 90 days to provide the agency time for a full review of the submission.
